Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
PTCT Quote, Financials, Valuation and Earnings
Last price:
$78.37
Seasonality move
:
4.55%
Day range:
$77.18 - $78.91
52-week range:
$35.95 - $87.50
Dividend yield:
0%
P/E ratio:
9.16x
P/S ratio:
3.62x
P/B ratio:
--
Volume:
308.2K
Avg. volume:
1.9M
1-year change:
72.81%
Market cap:
$6.3B
Revenue:
$806.8M
EPS (TTM):
$8.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
$175.5M | -$1.11 | 11.31% | -28.05% | $81.86 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
PYXS
Pyxis Oncology, Inc.
|
-- | -$0.34 | -100% | -44.91% | $7.18 |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.74 | 315.28% | -1.7% | $54.29 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
$78.37 | $81.86 | $6.3B | 9.16x | $0.00 | 0% | 3.62x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
PYXS
Pyxis Oncology, Inc.
|
$1.11 | $7.18 | $69.1M | -- | $0.00 | 0% | 24.12x |
|
SYRE
Spyre Therapeutics, Inc.
|
$33.05 | $54.29 | $2.6B | -- | $0.00 | 0% | 701.12x |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
161.23% | 0.296 | 8.36% | 2.20x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
PYXS
Pyxis Oncology, Inc.
|
21.71% | 3.830 | 13.82% | 4.01x |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | 2.219 | -- | 10.51x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
$187.7M | $3.5M | -382.54% | -- | 1.65% | -$322.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
PYXS
Pyxis Oncology, Inc.
|
-$527K | -$23.5M | -76.68% | -90.91% | -700.36% | -$13.3M |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$56.9M | -28.51% | -28.51% | -- | -$37.1M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
PTC Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PTCT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of -255.85%. PTC Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PTCT or NBY?
PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 4.45%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that PTC Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe PTC Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 5 1 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PTCT or NBY More Risky?
PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PTCT or NBY?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or NBY?
PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. PTC Therapeutics, Inc.'s net income of $15.9M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.16x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.62x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.62x 9.16x $211M $15.9M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns PTCT or PTN?
Palatin Technologies has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About PTCT or PTN?
PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 4.45%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than PTC Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 5 1 PTNPalatin Technologies0 0 0 -
Is PTCT or PTN More Risky?
PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PTCT or PTN?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or PTN?
PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Palatin Technologies quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Palatin Technologies's net income of --. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.16x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.62x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.62x 9.16x $211M $15.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns PTCT or PYXS?
Pyxis Oncology, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of -650.85%. PTC Therapeutics, Inc.'s return on equity of -- beat Pyxis Oncology, Inc.'s return on equity of -90.91%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M -
What do Analysts Say About PTCT or PYXS?
PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 4.45%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.18 which suggests that it could grow by 546.4%. Given that Pyxis Oncology, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 5 1 PYXSPyxis Oncology, Inc.7 1 0 -
Is PTCT or PYXS More Risky?
PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PTCT or PYXS?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or PYXS?
PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.16x while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.62x versus 24.12x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.62x 9.16x $211M $15.9M PYXSPyxis Oncology, Inc.24.12x -- -- -$22M
-
Which has Higher Returns PTCT or SYRE?
Spyre Therapeutics, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Spyre Therapeutics, Inc.'s return on equity of -28.51%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M -
What do Analysts Say About PTCT or SYRE?
PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 4.45%. On the other hand Spyre Therapeutics, Inc. has an analysts' consensus of $54.29 which suggests that it could grow by 64.25%. Given that Spyre Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 5 1 SYRESpyre Therapeutics, Inc.16 0 0 -
Is PTCT or SYRE More Risky?
PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Spyre Therapeutics, Inc. has a beta of 3.136, suggesting its more volatile than the S&P 500 by 213.562%.
-
Which is a Better Dividend Stock PTCT or SYRE?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Spyre Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or SYRE?
PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Spyre Therapeutics, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Spyre Therapeutics, Inc.'s net income of -$11.2M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.16x while Spyre Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.62x versus 701.12x for Spyre Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.62x 9.16x $211M $15.9M SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M
-
Which has Higher Returns PTCT or TOVX?
Theriva Biologics, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About PTCT or TOVX?
PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 4.45%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 5 1 TOVXTheriva Biologics, Inc.1 1 0 -
Is PTCT or TOVX More Risky?
PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock PTCT or TOVX?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or TOVX?
PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.16x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.62x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.62x 9.16x $211M $15.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
